Patents by Inventor B. RAVINDRAN

B. RAVINDRAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Composition for enhancing intra-cellular nitric oxide generation
    Patent number: 12778957
    Abstract: The present invention discloses a pharmaceutical composition comprising 1-{3-[9-methoxy-7-(2-methoxyphenyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-4-carbonyl]phenyl}imidazolidin-2-one; N-tert-butyl-2-{N-[(furan-2-yl)methyl]-2-[5-(4-methylphenyl)-2H-1,2,3,4-tetrazol-2-yl]acetamido}-2-(4-hydroxyphenyl)acetamide; 3-[2-(2-{[(6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(4hydroxyphenyl) methyl]amino}-4-oxo-4,5-dihydro-1,3-thiazol-5-yl) acetamido]benzoic acid; 2-oxo-2-(1H-pyrrol-2-yl)ethyl 2-[(4-fluorophenyl)methoxy]benzoate; and 5-(3-{[(3-bromo-4-hydroxy-5 methoxyphenyl) methylidene]amino}-2 (butylimino)-2,3-dihydro-1,3-thiazol-4-yl)-2-hydroxybenzamide. The components are small molecule antagonists that increase the intracellular nitric oxide level by inhibiting the interaction between Nitric oxide synthase interacting proteins and inducible Nitric oxide synthase.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: November 3, 2026
    Assignee: INSTITUTE OF LIFE SCIENCES
    Inventors: B. Ravindran, Diwakar Kumar Singh, Shailendra Asthana, Sagar Gaikwad, Dileep Vasudevan, Narottam Acharya
  • COMPOSITION FOR ENHANCING INTRA-CELLULAR NITRIC OXIDE GENERATION
    Publication number: 20240000786
    Abstract: The present invention discloses a pharmaceutical composition comprising 1-{3-[9-methoxy-7-(2-methoxyphenyl)-2,3,4,5-tetrahydro-1,4-benzoxazepine-4-carbonyl]phenyl}imidazolidin-2-one; N-tert-butyl-2-{N-[(furan-2-yl)methyl]-2-[5-(4-methylphenyl)-2H-1,2,3,4-tetrazol-2-yl]acetamido}-2-(4-hydroxyphenyl)acetamide; 3-[2-(2-{[(6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)(4hydroxyphenyl) methyl]amino}-4-oxo-4,5-dihydro-1,3-thiazol-5-yl) acetamido]benzoic acid; 2-oxo-2-(1H-pyrrol-2-yl)ethyl 2-[(4-fluorophenyl)methoxy]benzoate; and 5-(3-{[(3-bromo-4-hydroxy-5 methoxyphenyl) methylidene]amino}-2 (butylimino)-2,3-dihydro-1,3-thiazol-4-yl)-2-hydroxybenzamide. The components are small molecule antagonists that increase the intracellular nitric oxide level by inhibiting the interaction between Nitric oxide synthase interacting proteins and inducible Nitric oxide synthase.
    Type: Application
    Filed: November 15, 2021
    Publication date: January 4, 2024
    Inventors: B. RAVINDRAN, Diwakar Kumar SINGH, Shailendra ASTHANA, Sagar GAIKWAD, Dileep VASUDEVAN, Narottam ACHARYA